Jan C Brase - Novartis | 人才画像

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 110 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Tolérance Et Efficacité Antitumorale De BAY 2927088 Chez Des Patients Atteints D’un Cancer Bronchique Non À Petites Cellules Muté HER2 : Résultats D’une Cohorte D’expansion De L’étude De Phase I/II SOHO-01

N. Girard, T.M. Kim, H.R. Kim,H.H. Loong,Y. Shinno, S. Lu, Y. Fang, J. Zhao, K. Nishino, K.H. Lee, L. Miao, T. Sakamoto, E. Felip, T.Y. Yang, C.A. Dooms,D. Shao-Weng Tan, X. Le,J.C. Brase, S. Cousin, M. Perol

Revue des Maladies Respiratoires Actualités（2025）

Cited0Views0Bibtex

The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials

Benjamin J Solomon,Daniel S W Tan,Gilberto de Castro,Manuel Cobo,Marina Chiara Garassino,Jun Zhang,Bruce E Johnson,Jay M Lee,Pilar Garrido, Andrew A Butler, Marc R Pelletier,Alexander Savchenko, Lexiang Ji,Jan C Brase, Rafael Caparica,David Demanse, Jincheng Wu, Claudia Bossen,Tony Mok

Cancer research communicationsno. 4 (2025): 632-646

Cited0Views0WOSBibtex

SOHO-02 : Étude De Phase III Évaluant BAY 2927088 Chez Des Patients Atteints D’un Cancer Bronchique Non À Petites Cellules Avec Mutations Activatrices De HER2 Localement Avancé Ou Métastatique

K. Goto,J.C. Brase, D. Debieuvre, S. Cousin, N. Girard,J. Raimbourg, D. Planchard, J. Bennouna,M. Wislez, A.C. Toffart,F. Guisier,R. Descourt,T. Egenod, C. Travert, J. Xu, S.F. Pu, M. Montague-Dale,L. Mongay Soler, A. Passaro, O. Galut

Revue des Maladies Respiratoires Actualités（2025）

Cited0Views0Bibtex

SOHO-02: Phase III Trial of BAY 2927088 in Patients with Locally Advanced or Metastatic NSCLC with HER2-Activating Mutations

K. Goto,J. C. Brase, J. Xu, S. -F. Pu, M. Montague-Dale,L. Mongay Soler,A. Passaro

JOURNAL OF THORACIC ONCOLOGY（2024）

Cited0Views0Bibtex

EP.12H.08 SOHO-02: Phase III Trial of BAY 2927088 in Patients with Locally Advanced or Metastatic NSCLC with HER2-Activating Mutations

K. Goto,J.C. Brase, J. Xu, S.-F. Pu, M. Montague-Dale,L. Mongay Soler,A. Passaro

Journal of Thoracic Oncologyno. 10 (2024): S660

Cited0Views0Bibtex

1395Tip A Randomized Phase III Trial Evaluating Oral BAY 2927088, Compared with Standard of Care, As First-Line Treatment of Locally Advanced or Metastatic NSCLC Harboring HER2-activating Mutations (SOHO-02)

A. Passaro,J.C. Brase, J. Xu,L. Mongay Soler, K. Goto

Annals of Oncology (2024): S873-S874

Cited0Views0Bibtex

ERBB2 and TOP2A in Breast Cancer: A Comprehensive Analysis of Gene Amplification, RNA Levels, and Protein Expression and Their Influence on Prognosis and Prediction

Jan C. Brase,Marcus Schmidt,Thomas Fischbach,Holger Sueltmann,Hans Bojar,Heinz Koelbl,Birte Hellwig,Joerg Rahnenfuehrer,Jan G. Hengstler,Mathias C. Gehrmann

crossref（2023）

Cited121Views0WOSBibtex

121

Supplementary Figures 1-5 from Genome-wide DNA Methylation Events in TMPRSS2–ERG Fusion-Negative Prostate Cancers Implicate an EZH2-Dependent Mechanism with Mir-26A Hypermethylation

Stefan T. Börno,Axel Fischer,Martin Kerick,Maria Fälth,Mark Laible,Jan C. Brase,Ruprecht Kuner, Andreas Dahl,Christina Grimm,Behnam Sayanjali,Melanie Isau, Christina Röhr,Andrea Wunderlich,Bernd Timmermann, Rainer Claus,Christoph Plass,Markus Graefen,Ronald Simon,Francesca Demichelis,Mark A. Rubin,Guido Sauter,Thorsten Schlomm,Holger Sültmann,Hans Lehrach,Michal R. Schweiger

openalex（2023）

Cited0Views0Bibtex

Supplementary Tables 1-4 from Genome-wide DNA Methylation Events in TMPRSS2–ERG Fusion-Negative Prostate Cancers Implicate an EZH2-Dependent Mechanism with Mir-26A Hypermethylation

openalex（2023）

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn